ALOX5 and asthma: Despite considerable efforts made towards the development of efficient drugs that target 5-LOX enzyme, zileuton remains the only clinically approved 5-LOX inhibitor in the treatment of asthma but its use is limited due to severe side effects such as, weak potency, liver toxicity, and an unfavorable pharmacokinetic profile with a short half-life [12, 13].